Application gaps in Medicine

Representative open questions

Showing 30 of 513 — one per source paper, highest-quality first.

• Longitudinal localization of leukaemic stem cells between the metaphysis and central marrow governs their behaviour (2026) · doi

  While reference 66 demonstrates that manipulating niche composition (using Cxcl12fl/fl and Scf fl/fl mice) protects haematopoietic stem cells during infection, the extent to which these niche modifications differentially affect leukaemic stem cell behavior in metaphyseal versus central marrow compartments—and whether this translates to improved chemotherapy sensitivity in AML—remains experimentally unaddressed.

• Bi-Polar Bioenergetic Intervention via a Pathology Self-Adaptive Single-Atom Nanocatalyst for Diabetic Tumor Postoperative Management (2026) · doi

  The wound healing assays were conducted in dorsal skin wounds adjacent to resected melanomas in diabetic mice. Translation to clinically relevant surgical wound scenarios (incisional wounds, wounds with varying closure geometries, different tissue depths) in diabetic patients remains untested.

• Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome (2026) · doi

  Only 81% of women in the IVF cohort achieved pregnancy, and a zero-inflation term was necessary to model the underdispersed cycle-to-pregnancy data; characterizing the clinical and genetic factors driving the 19% non-pregnancy group (treatment cessation without conception) would clarify PCOS-associated reproductive failure mechanisms.

• Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease (2026) · doi

  Prospective clinical studies are required to confirm the predictive value and clinical utility of the MASLD-HCC signature (EpCAM, DTNA, KPNA2) for patient risk stratification and HCC progression, as current validation is limited to retrospective cohort analysis without temporal follow-up data.

• The impact of traumatic injury on the respiratory system; a narrative review of injury-associated and clinically-induced mechanisms of trauma-associated pneumonia (2026) · doi

  The persistent inflammation, immunosuppression, and catabolism (PIICS) syndrome has been described in trauma patients, but specific interventions targeting the compensatory anti-inflammatory response (CARS) phase to prevent secondary pneumonia in this population require clinical trial development and validation.

• FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) – a randomized, open-label, multicenter phase II trial protocol (2026) · doi

  The hypofractionated, accelerated CRT approach has been extensively studied in breast cancer but not systematically in locally advanced unresectable NSCLC. Direct comparative effectiveness data between this condensed schedule and conventional fractionation regarding toxicity profiles in adjacent organs at risk (esophagus, heart, lungs) specific to NSCLC geometry are lacking.

• Impact of Health Education and Preventive Interventions on Non- Communicable Diseases in Rural Communities: A Community-Based Randomized Controlled Trial (2026) · doi

  Participants in the control group failed to maintain weight loss due to lack of organized support for lifestyle choices, but the paper does not identify what specific support structures, follow-up frequencies, or community-based mechanisms are needed to sustain behavioral change in rural populations with hypertension and obesity.

• From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma (2026) · doi

  Therapeutic targeting of organelle pathways including autophagy inhibitors, mitochondrial dynamics modulators, and ER stress inducers must be evaluated in preclinical cHCC-CCA models with systematic assessment of whether treatment efficacy correlates with the predominant lineage component (hepatocellular versus cholangiocarcinoma).

• Integration of biomedical imaging and sensing technologies with AI-IoT for Materiovigilance and predictive modeling of stillbirth risk in maternal-fetal health monitoring (2026) · doi

  Multi-modal AI systems capable of combining clinical, physiological, and molecular data for real-time stillbirth risk assessment have not been developed or clinically validated. Integration of continuous IoT monitoring with biomarker-based diagnostics to create personalized treatment pathways in precision obstetrics remains unexplored.

• Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer (2026) · doi

  The study tested paclitaxel, doxorubicin, and carboplatin in combination with GRK2 or Aurora B inhibitors, but did not systematically evaluate whether the identified proteogenomic resistance mechanisms are specific to these chemotherapy agents or translate to other drug classes used in TNBC treatment (e.g., platinum-taxane combinations, immunotherapy combinations).

• Exercise benefits in metabolism on cardiovascular disease (2026) · doi

  The associations between sedentary behavior and cardiovascular disease mortality have been examined in meta-analyses of over 850,000 participants, but the differential effects across varying physical activity levels and exercise intensities in specific cardiovascular disease subpopulations (heart failure, coronary artery disease) warrant targeted investigation.

• Effectiveness of screening modalities for early detection of diabetic retinopathy: a systematic review and meta-analysis of tele-ophthalmology, AI-based tools, and conventional methods (2026) · doi

  Clinical informatics tools for DR screening workflow integration in primary care have been limited to EHR-enabled clinics with fundus imaging; practical implementation and workflow efficiency outcomes of AI-assisted screening in non-EHR primary care environments need evaluation.

• Novel endogenous protein-based strategies to inhibit clinically relevant bacterial AB-type toxins including pertussis toxin (2026) · doi

  α1AT-containing drugs are already approved for α1AT deficiency treatment, but their therapeutic efficacy as off-label inhibitors of pertussis toxin has not been evaluated in clinical or preclinical in vivo studies. Systematic investigation of α1AT pharmacokinetics and toxin-neutralizing capacity specifically in pertussis toxin-mediated disease models is needed.

• Antibody–drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges (2026) · doi

  Castro et al. (2024) emphasize incorporating patient preferences into target product profile development for cutaneous leishmaniasis, but the specific requirements for antibody-drug conjugate design parameters (payload potency, linker stability, immunogenicity) tailored to neglected tropical disease patient populations remain undefined.

• Unveiling the relationship of the comorbidity between depression and type 2 diabetes mellitus: a macro analysis and micro interpretation (2026) · doi

  The integrated treatment framework combining psychological interventions with metabolic management for depression and T2DM comorbidity lacks specification regarding implementation protocols in primary health care settings. Research is needed on translating HPA axis and BDNF-targeted interventions into practical primary care workflows across different healthcare systems.

• Artificial intelligence in acute and critical care: current challenges and strategic solutions (2026) · doi

  Human-in-the-loop quality control mechanisms for AI systems in acute and critical care lack concrete specifications regarding workflow integration, decision override protocols, and clinician feedback loops. The paper mentions this requirement but does not detail what specific human-AI interaction patterns should be validated or how to measure their effectiveness in real clinical environments.

• Immune molecular mechanisms of PANoptosis in sepsis-induced acute kidney injury (2026) · doi

  Traditional Chinese Medicine interventions (e.g., Dachengqi decoction, Dahuang Gancao Decoction) are mentioned as potential therapeutic agents for PANoptosis in sepsis-induced AKI, but controlled clinical trials comparing these compounds with standard sepsis treatments and validating their specific molecular targets (STING, GSDMD, RIPK3) are absent.

• Bioactive and Ion-releasing materials in minimum intervention dentistry: a clinical pathway from prevention to restorative treatment (2026) · doi

  Integration of AI-assisted material selection with 3D printing and bioprinting technologies for producing patient-specific bioactive restorations requires validation studies measuring clinical outcomes in deep caries management with liners and dentin substitutes under selective caries removal protocols.

• Transcriptional regulation in cardiovascular aging (2026) · doi

  SIRT2 activators have not been systematically screened or developed for cardiovascular aging applications. The paper identifies SIRT2 as a key epigenetic modifier but lacks concrete chemical development pipelines or candidate compounds for clinical translation targeting age-related cardiovascular disease.

• Artificial intelligence approaches to predicting treatment non-adherence in chronic diseases: a narrative review (2026) · doi

  Relatively few studies have evaluated AI-based adherence prediction models prospectively in actual clinical workflows, highlighting a critical gap between methodological development and real-world implementation. Future research must assess technical success factors alongside organizational readiness, clinician engagement, governance oversight, and human-centered design considerations in resource-limited healthcare settings.

• Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review) (2026) · doi

  PSMA-based imaging is advancing in localized and advanced prostate cancer (reference 28), but integration of quantitative PSMA-PET/CT radiomics features with deep learning-extracted histopathological features and clinical variables in unified multimodal AI models for treatment selection has not been thoroughly developed.

• Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers (2026) · doi

  While the paper reviews quercetin's antidiabetic mechanisms in rodent models (streptozotocin-induced, db/db, high-fructose-fed rats), translation to human metabolic disease cohorts remains absent. Randomized controlled trials with quercetin nanoformulations in type 2 diabetic patients or obese individuals measuring insulin signaling biomarkers (phosphorylated Akt, glucose transporter expression), inflammatory cytokines (TNF-α, IL-6), and glucose homeostasis parameters are needed to establish clinical efficacy beyond animal models.

• A High-Dimensional Genomic Framework for Leukemia Subtype Classification Using LightGBM and SHAP-based Explainable AI (2026) · doi

  While SHAP waterfall plots provided case-level explainability for individual patient predictions in the LightGBM model, the study did not assess how clinician trust and diagnostic decision-making change when presented with these AI explanations; prospective clinical validation studies are needed to quantify the impact of SHAP-based interpretability on clinical adoption and physician confidence.

• Biochemical Markers In Seminal Plasma And Serum: A Comparative Assessment In Fertile And Infertile Men (2026) · doi

  Clinical studies directly correlating seminal plasma biomarkers with assisted reproductive technology outcomes are limited. Future longitudinal cohort studies must monitor how SP biomarkers for male fertility (Cu, SGOT, LDH, cholesterol) evolve over time and in response to different therapeutic drugs.

• A sham-controlled randomised trial evaluating the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous vagal sensory stimulation in uncontrolled hypertensive patients: rationale and study design of the SCRATCH-HTN study (2026) · doi

  The study's efficacy threshold is defined as >10 mmHg reduction in systolic blood pressure lasting >1 month post-discontinuation, but does not establish whether this criterion applies uniformly across subpopulations with different baseline hypertension severity, medication burden, or comorbidities in uncontrolled hypertensive patients.

• Medical clinical minds meet artificial intelligence: Italian physicians' knowledge, attitudes, and concordance between Italian physicians and AI-generated diagnoses. A national cross-sectional study (2026) · doi

  The study identified that excessive confidence in AI-physician concordance could lead to 'collective blindness' in atypical or rare cases, but provides no empirical framework or methodology to detect, quantify, or mitigate this risk in integrated clinical workflows. Future research must develop specific metrics to identify and prevent shared diagnostic limitations.

• Exploring the mechanism of baicalein on choroid melanoma based on network pharmacology, transcriptomics and experimental verification (2026) · doi

  Comprehensive pharmacokinetic/pharmacodynamic (PK/PD) profiling and GLP-compliant toxicity testing were not performed for baicalein in the choroidal melanoma model, and the compound's known limitations of low oral bioavailability and short half-life require specific drug delivery system optimization before clinical translation.

• Deep learning-based differential diagnosis of major depression and bipolar disorder using microglia-cellular sensors and patient-derived small extracellular vesicles (2026) · doi

  The 24-hour sEV incubation period and image acquisition pipeline have been evaluated for turnaround time feasibility, but clinical workflow integration using automated high-content imaging platforms (Opera Phenix, ImageXpress Micro Confocal) has not been prospectively validated in multi-site clinical settings for mood disorder diagnosis.

• Global research trends in stroke and gut microbiota: a multi-database bibliometric analysis and cross-validation study (2026) · doi

  While animal studies demonstrate that modulating gut microbiota can reverse dysbiosis-related inflammation and metabolic abnormalities to reduce stroke risk, there is a specific gap in validated translational models that bridge murine microbiota intervention outcomes to human clinical stroke prevention and post-stroke recovery protocols.

• The role of different types of programmed cell death in myocardial fibrosis: from mechanisms to therapeutics (2026) · doi

  The clinical translation pathway from epigenetic therapy targeting specific histone modifications, DNA methylation, or miR-21/Spry1/ERK-MAPK axis in basic research to Phase I/II clinical trials for myocardial fibrosis has not been systematized or benchmarked.